Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics,
and consumer health products, today announced that it has added Uwe
Röhrhoff as an independent member of its Board of Directors, effective
at the next regularly scheduled meeting of its Board. The appointment
follows the resignations of Chinh Chu and E. Bruce McEvoy, the designees
of its former equity sponsor The Blackstone Group, L.P., after the sale
of Blackstone’s interest in the Company.
In addition, the Board decreased its size from 10 directors to 9,
appointed Catalent President and Chief Executive Officer John Chiminski,
an existing member of the Board, as its Chair, and appointed Jack Stahl,
an existing independent member of the Board, as its Lead Director.
Uwe Röhrhoff has been the Chief Executive Officer of Gerresheimer AG
since 2010. Mr. Röhrhoff has been with Gerresheimer AG, a German
manufacturer of primary packaging products for medication and drug
delivery devices made of special-purpose glass and plastics, since 1991.
He initially headed the Finance and Controllership functions of
Gerresheimer AG’s Molded Glass Division (“Molded Glass”) before assuming
the role of Vice President, Controller of Kimble USA, Inc., an American
subsidiary of Gerresheimer AG, from 1996 to 1998. In 1998, Mr. Röhrhoff
was appointed head of Molded Glass on an international level as well as
Chief Executive Officer and Chief Financial Officer of Tettauer
Glashüttenwerke AG, another subsidiary of Gerresheimer AG. From 2001
until 2007, Mr. Röhrhoff served as CEO and CFO (until 2003) of Kimble
USA. In 2003, Mr. Röhrhoff was appointed to the Management Board of the
Gerresheimer Group and continues to hold that position. During
Gerresheimer AG’s restructuring from 2007 through 2013, Mr. Röhrhoff was
responsible for Molded Glass and Gerresheimer AG’s Life Science Research
Division. In 2013, he became responsible for Gerresheimer AG’s Primary
Packaging Glass Division. Mr. Röhrhoff started his career in the finance
department of Scheidt & Bachmann GmbH.
“We are excited to have this astute and able executive join our Board,”
said Mr. Chiminski. “His extensive experience in servicing the
pharmaceutical industry will inform his advice and decisions as the
Board guides our continued growth and industry leadership.”
Mr. Röhrhoff commented, “I am pleased to join the Catalent Board and
look forward to working with the Board and the Company’s capable
management team.”
Mr. Röhrhoff holds a business studies degree from the University of
Cologne.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs more than 9,500
people, including over 1,400 scientists, at more than 30 facilities
across 5 continents and in fiscal 2016 generated $1.85 billion in annual
revenue. Catalent is headquartered in Somerset, N.J. For more
information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
Catalent, Inc.
Investors:
Thomas Castellano, 732-537-6325
investors@catalent.com